|
Serous Tubal Intraepithelial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The secretary cell outgrowth (SCOUT) with TP53 mutations progresses to HGSC via the p53 signature, serous intraepithelial lesion (STIL), and serous intraepithelial carcinoma (STIC), indicating that TP53 mutation is associated with carcinogenesis of HGSC.
|
31689961 |
2019 |
|
Serous Tubal Intraepithelial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Identical TP53 mutations in the peritoneal serous carcinoma and the preceding STIC established their clonal origin.
|
30894273 |
2019 |
|
Serous Tubal Intraepithelial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
While L1ORF1p may not be prognostic in gynecological cancers, it may be useful clinically as a diagnostic IHC marker for p53 null STIC lesions and this warrants further investigation.
|
31220479 |
2019 |
|
Serous Tubal Intraepithelial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Two deleterious somatic mutations in TP53 and BRCA2 genes were shared between retroperitoneal HGSC and STIC.
|
30744657 |
2019 |
|
Serous Tubal Intraepithelial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Combined RB family inactivation and Tp53 mutation in Pax8 + FTE caused Serous Tubal Intraepithelial Carcinoma (STIC), which metastasized rapidly to the ovarian surface.
|
31772167 |
2019 |
|
Serous Tubal Intraepithelial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In particular, TET1 was highly expressed in serous tubal intraepithelial carcinoma (STIC), a currently accepted type II EOC precursor, and inversely correlated with TP53 mutations.
|
30883733 |
2019 |
|
Serous Tubal Intraepithelial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Because clonal Tp53 mutations are a defining feature of HGSC, including their associated STICs, we analyzed 4 cases of bilateral serous tubal intraepithelial neoplasia (STIN), including STIC and Tp53-mutated serous tubal intraepithelial lesions (STILs), associated with HGSC to determine whether they contained the same or different p53 mutations.
|
29901519 |
2019 |
|
Serous Tubal Intraepithelial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Serial sectioning revealed a previously unrecognized STIC/HGSC in 3 of 32 (9.3%) and ESPs in 13 (40.6%).Twelve contained TP53 mutations.
|
30043522 |
2018 |
|
Serous Tubal Intraepithelial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serous tubal intraepithelial carcinoma was identified by hematoxylin and eosin staining and confirmed by positive Ki-67 and p53 immunohistochemical staining of tissue sections.
|
30095490 |
2018 |
|
Serous Tubal Intraepithelial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
All 10 bilateral tumors and all 11 PCS-associated STICs showed a similar p53 immunostaining pattern.
|
27059324 |
2016 |
|
Serous Tubal Intraepithelial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study demonstrates that STMN1 and p16 are sensitive and specific adjunct biomarkers that, when used with p53 and Ki-67, improve the diagnostic accuracy of STIC.
|
26206555 |
2015 |
|
Serous Tubal Intraepithelial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
One of these genes, Top2a, which encodes topoisomerase IIα, was shown by immunohistochemistry to be concurrently expressed with elevated p53 and was specifically elevated in mouse STICs but not in the surrounding tissues.
|
24652535 |
2014 |
|
Serous Tubal Intraepithelial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The morphologic and immunohistochemical features (aberrant p53 and MIB-1) of these STICs were similar to those expected in high-risk women.
|
24820399 |
2014 |
|
Serous Tubal Intraepithelial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry for IMP3 and p53 was performed and evaluated in 48 HGSCs with STIC, 62 HGSCs without STIC, and 60 benign cases as negative controls.
|
25038792 |
2014 |
|
Serous Tubal Intraepithelial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The presence and location of serous tubal intraepithelial carcinoma (STIC), p53 overexpression (≥ 6 consecutively stained nuclei), Ki67 overexpression, atypia/low grade dysplasia and epithelial hyperplasia were compared between BRCA carriers and controls.
|
25026639 |
2014 |
|
Serous Tubal Intraepithelial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions.
|
21990067 |
2012 |
|
Serous Tubal Intraepithelial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that the overexpression of laminin γ1 immunoreactivity and alteration of its staining pattern in STICs can serve as a useful tissue biomarker, especially for those STICs that are negative for p53 and have a low Ki-67 labeling index.
|
22892598 |
2012 |
|
Serous Tubal Intraepithelial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Twenty-two STICs from 15 patients with concurrent but discrete HGSCs were analyzed for telomere length on formalin-fixed, paraffin-embedded sections by conducting p53 immunofluorescence to assist in identifying STICs and telomere-specific FISH.
|
20431479 |
2010 |
|
Serous Tubal Intraepithelial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Twenty-one cases were selected and classified as STIC or benign, using both hematoxylin and eosin and immunohistochemical stains for p53 and MIB-1.
|
20567141 |
2010 |
|
Serous Tubal Intraepithelial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunostaining for p53 and Wilms tumor-1 was performed on all cases with STIC. p53 mutation analysis was performed in a subset of matched STICs and endometrial tumors.
|
19483636 |
2009 |